Verastem (VSTM) Total Debt (2017 - 2026)
Verastem's quarterly Total Debt came in at $73.1 million in Q1 2026, up 2.3% year-on-year from $71.5 million in Q1 2025, and down 4.21% quarter-over-quarter from $76.3 million in Q4 2025.
Verastem has reported Total Debt for 9 years, with the latest figure at $73.1 million in Q1 2026.
- For the quarter ending Q1 2026, Total Debt rose 2.3% year-over-year to $73.1 million; the trailing twelve-month figure through Mar 2026 stood at $73.1 million (up 2.3% YoY), and the FY2025 full-year result was $76.3 million, up 87.43% from the prior year.
- Total Debt for Q1 2026 stood at $73.1 million, down from $76.3 million in the prior quarter.
- The five-year high for Total Debt was $78.1 million in Q3 2025, with the low at $24.2 million in Q1 2022.
- Average Total Debt over 5 years is $46.6 million, with a median of $40.1 million recorded in 2024.
- Year-over-year, Total Debt gained 1.39% in 2024 and soared 92.82% in 2025.
- Tracing VSTM's Total Debt over 5 years: stood at $24.5 million in 2022, then surged by 63.44% to $40.1 million in 2023, then rose by 1.59% to $40.7 million in 2024, then jumped by 87.43% to $76.3 million in 2025, then declined by 4.21% to $73.1 million in 2026.
- The last three Total Debt figures came in at $73.1 million (Q1 2026), $76.3 million (Q4 2025), and $78.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.96 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Verastem | 425.60 Mn | 243.93 Mn | 15.90 Mn | 73.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.12 Mn |
| Dec 31, 2025 | 76.33 Mn |
| Sep 30, 2025 | 78.12 Mn |
| Jun 30, 2025 | 74.27 Mn |
| Mar 31, 2025 | 71.48 Mn |
| Dec 31, 2024 | 40.72 Mn |
| Sep 30, 2024 | 40.52 Mn |
| Jun 30, 2024 | 40.32 Mn |
| Mar 31, 2024 | 40.12 Mn |
| Dec 31, 2023 | 40.09 Mn |
| Sep 30, 2023 | 39.91 Mn |
| Jun 30, 2023 | 39.74 Mn |
| Mar 31, 2023 | 39.57 Mn |
| Dec 31, 2022 | 24.53 Mn |
| Sep 30, 2022 | 24.40 Mn |
| Jun 30, 2022 | 24.28 Mn |
| Mar 31, 2022 | 24.16 Mn |
| Sep 30, 2020 | 35.70 Mn |
| Jun 30, 2020 | 35.49 Mn |
| Mar 31, 2020 | 35.28 Mn |
| Dec 31, 2019 | 35.52 Mn |
| Sep 30, 2019 | 34.88 Mn |
| Jun 30, 2019 | 34.67 Mn |
| Mar 31, 2019 | 24.81 Mn |
| Dec 31, 2018 | 25.22 Mn |
| Sep 30, 2018 | 25.06 Mn |
| Jun 30, 2018 | 24.90 Mn |
| Mar 31, 2018 | 14.91 Mn |
| Dec 31, 2017 | 14.83 Mn |
| Sep 30, 2017 | 2.34 Mn |
| Jun 30, 2017 | 2.29 Mn |
| Mar 31, 2017 | 2.25 Mn |